Skip to main content

Table 5 One-way sensitivity analyses comparing cervical cancer screening only and cervical cancer screening associated with a quadrivalent HPV vaccination programme

From: Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

Parameters ICER (£/QALYs) ICER (£/LYs)
Base case 21,059 34,687
Vaccine duration   
10 years 68,417 116,743
10 years + booster to achieve lifetime protection 26,782 44,114
20 years 30,777 52,578
Multiple infections   
15% 24,085 39,842
Vaccine efficacy   
85% 25,081 40,831
Vaccine coverage   
50% 21,581 34,426
Screening coverage rate   
-50% 16,266. 35,476
-10% 19,926 34,681
Screening, diagnosis and treatment costs   
-20% 21,717 35,771
+20% 20,401 33,602
Vaccine costs   
70 £ 19,450 32,036
80 £ 22,668 37,337
Utilities   
25% decrease for screening utilities; 1-year duration for time with cancer 25,600  
25% increase in time with disease; 5-year duration for time with cancer 19,840  
Cancer utilities only (5 year duration) 27,954  
Discount rates   
0% costs; 0% medical benefit 3,123 4,122
3% costs; 3% medical benefit 17,089 27,066
3,5% costs; 1,5% medical benefit 9,653 13,797
5% costs; 5% medical benefit 36,618 68,760
Multivariate Sensitivity Analyses   
10 years duration, 50% coverage, 85% efficacy 84,925 140,705
Lifetime duration, 90% coverage, 100% efficacy 20,316 33,752
Changes to Screening (assuming base case assumptions for the vaccine)   
Screening every 5 years starting at age 25 13,449 36,712
Screening starting at age 26 20,724 34,441
Screening starting at age 28 16,527 34,153
Screening starting at age 30 13,680 34,989
  1. Base case discount rate: 3.5% for costs and medical benefits